Cancer Research SABCS Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olson, L. E.
Right arrow Articles by Reeves, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olson, L. E.
Right arrow Articles by Reeves, R. H.
[Cancer Research 63, 6602-6606, October 15, 2003]
© 2003 American Association for Cancer Research

Regular Articles

Protection from Doxorubicin-Induced Cardiac Toxicity in Mice with a Null Allele of Carbonyl Reductase 11

Lisa E. Olson, Djahida Bedja, Sara J. Alvey, A. J. Cardounel, Kathleen L. Gabrielson and Roger H. Reeves2

Johns Hopkins University School of Medicine, Department of Physiology, Baltimore, Maryland 21205 [L. E. O., R. H. R.]; Johns Hopkins University School of Medicine, Department of Comparative Medicine, Baltimore, Maryland 21287 [D. B., S. J. A., K. L. G.]; and Heart and Lung Research Institute, Ohio State University, Columbus, Ohio 43210 [A. J. C.]

Doxorubicin is a highly effective antineoplastic agent, but it can produce the serious side effects of acute cardiac injury and chronic congestive heart failure. Carbonyl reductase (CBR) has been implicated in the development of doxorubicin-induced cardiotoxicity. To test whether a decrease in CBR levels was protective against doxorubicin toxicity, we created a null allele of the Cbr1 gene. Mice with one functional copy of the gene (Cbr1 +/-) were healthy and grossly normal despite having decreased levels of Cbr1 transcript and protein. Control and Cbr1 +/- mice were administered doxorubicin at 20 mg/kg i.p. Cbr1 +/- mice showed decreased circulating levels of the cardiotoxic metabolite, doxorubicinol, after administration. Within 2 weeks, 91% of wild-type mice were severely affected (n = 11) compared with 18% of Cbr1 +/- mice (n = 11). Echocardiography and histological analysis showed that Cbr1 +/- mice were protected from gross and cellular level pathologies associated with doxorubicin treatment. Demonstration that inhibition of carbonyl reductase blocks the toxic effects on the heart has important implications for improving the use of doxorubicin in chemotherapy.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J.-Y. Choi, W. E. Barlow, K. S. Albain, C.-C. Hong, J. G. Blanco, R. B. Livingston, W. Davis, J. M. Rae, I-T. Yeh, L. F. Hutchins, et al.
Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial
Clin. Cancer Res., August 15, 2009; 15(16): 5258 - 5266.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
V. Gonzalez-Covarrubias, J. Zhang, J. L. Kalabus, M. V. Relling, and J. G. Blanco
Pharmacogenetics of Human Carbonyl Reductase 1 (CBR1) in Livers from Black and White Donors
Drug Metab. Dispos., February 1, 2009; 37(2): 400 - 407.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Kassner, K. Huse, H.-J. Martin, U. Godtel-Armbrust, A. Metzger, I. Meineke, J. Brockmoller, K. Klein, U. M. Zanger, E. Maser, et al.
Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver
Drug Metab. Dispos., October 1, 2008; 36(10): 2113 - 2120.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Fang, J. Gu, F. Xie, M. Behr, W. Yang, E. D. Abel, and X. Ding
Deletion of the NADPH-Cytochrome P450 Reductase Gene in Cardiomyocytes Does Not Protect Mice against Doxorubicin-Mediated Acute Cardiac Toxicity
Drug Metab. Dispos., August 1, 2008; 36(8): 1722 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. H. Takahashi, O. S. Bains, T. A. Pfeifer, T. A. Grigliatti, R. E. Reid, and K. W. Riggs
Aldo-Keto Reductase 1C2 Fails to Metabolize Doxorubicin and Daunorubicin in Vitro
Drug Metab. Dispos., June 1, 2008; 36(6): 991 - 994.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
D. Cihakova, J. G. Barin, M. Afanasyeva, M. Kimura, D. Fairweather, M. Berg, M. V. Talor, G. C. Baldeviano, S. Frisancho, K. Gabrielson, et al.
Interleukin-13 Protects Against Experimental Autoimmune Myocarditis by Regulating Macrophage Differentiation
Am. J. Pathol., May 1, 2008; 172(5): 1195 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
V. Gonzalez-Covarrubias, D. Ghosh, S. S. Lakhman, L. Pendyala, and J. G. Blanco
A Functional Genetic Polymorphism on Human Carbonyl Reductase 1 (CBR1 V88I) Impacts on Catalytic Activity and NADPH Binding Affinity
Drug Metab. Dispos., June 1, 2007; 35(6): 973 - 980.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Yokoyama, B. Xin, T. Shigeto, M. Umemoto, A. Kasai-Sakamoto, M. Futagami, S. Tsuchida, F. Al-Mulla, and H. Mizunuma
Clofibric acid, a peroxisome proliferator-activated receptor {alpha} ligand, inhibits growth of human ovarian cancer
Mol. Cancer Ther., April 1, 2007; 6(4): 1379 - 1386.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Salvatorelli, P. Menna, S. Cascegna, G. Liberi, A. M. Calafiore, L. Gianni, and G. Minotti
Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 424 - 433.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. Li, R. Y. T. Sung, W. Z. Huang, M. Yang, N. H. Pong, S. M. Lee, W. Y. Chan, H. Zhao, M. Y. To, T. F. Fok, et al.
Thrombopoietin Protects Against In Vitro and In Vivo Cardiotoxicity Induced by Doxorubicin
Circulation, May 9, 2006; 113(18): 2211 - 2220.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Salvatorelli, S. Guarnieri, P. Menna, G. Liberi, A. M. Calafiore, M. A. Mariggio, A. Mordente, L. Gianni, and G. Minotti
Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart: RELATIVE IMPORTANCE OF VESICULAR SEQUESTRATION AND IMPAIRED EFFICIENCY OF ELECTRON ADDITION
J. Biol. Chem., April 21, 2006; 281(16): 10990 - 11001.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Afanasyeva, D. Georgakopoulos, D. F. Belardi, D. Bedja, D. Fairweather, Y. Wang, Z. Kaya, K. L. Gabrielson, E. R. Rodriguez, P. Caturegli, et al.
Impaired up-regulation of CD25 on CD4+ T cells in IFN-{gamma} knockout mice is associated with progression of myocarditis to heart failure
PNAS, January 4, 2005; 102(1): 180 - 185.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Nozaki, T. Shishido, Y. Takeishi, and I. Kubota
Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2-Knockout Mice
Circulation, November 2, 2004; 110(18): 2869 - 2874.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
L. E. Olson, J. T. Richtsmeier, J. Leszl, and R. H. Reeves
A Chromosome 21 Critical Region Does Not Cause Specific Down Syndrome Phenotypes
Science, October 22, 2004; 306(5696): 687 - 690.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.